Market Cap 32.06M
Revenue (ttm) 8.98M
Net Income (ttm) -48.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -543.32%
Debt to Equity Ratio 0.00
Volume 73,992
Avg Vol 118,016
Day's Range N/A - N/A
Shares Out 46.84M
Stochastic %K 15%
Beta 0.78
Analysts Strong Sell
Price Target $3.67

Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid S...

Industry: Medical Devices
Sector: Healthcare
Phone: 888 776 6804
Address:
6303 Waterford District Drive, Suite 215, Miami, United States
zigsfrd
zigsfrd Jul. 30 at 2:25 PM
$NSPR With the booming sales we've experienced, don't you wonder what took so long? Gleason was not effective, and no amount of corporate glad handing could cover it.
0 · Reply
GiveHerTheDD
GiveHerTheDD Jul. 30 at 12:13 AM
$NSPR Slimming the board and c-suite for recommercialization seems like a good plan 🙌
1 · Reply
focafoca99
focafoca99 Jul. 29 at 9:10 PM
$NSPR Chief Commercial Officer Shane Gleason will leave after the company eliminated his position, effective July 31. https://www.rapidticker.com/news/nspr-sec-filing-b2261c
0 · Reply
pmitsie
pmitsie Jul. 27 at 4:09 PM
$NSPR Not a pretty chat. I fear the worst.
1 · Reply
Thespectator
Thespectator Jul. 25 at 9:38 PM
$NSPR 1:10 r/s cooking up, any day now 😉
1 · Reply
focafoca99
focafoca99 Jul. 23 at 9:10 PM
$NSPR faced a Nasdaq delisting notice for failing the $1.00 minimum bid price requirement. https://www.rapidticker.com/news/nspr-sec-filing-9d4fa1
0 · Reply
Meterdoc
Meterdoc Jul. 21 at 10:23 PM
$NSPR when is the flush? It’ll be epic!❤️
1 · Reply
GiveHerTheDD
GiveHerTheDD Jul. 19 at 2:26 AM
$NSPR Catherine Jennings, President of Vascular Peripheral at Boston Scientific, just left her position to pursue a new medtech venture. While not really unusual, both Martin and Shane liked her Linkedin post. 👀 Make it happen! That is the reassurance everyone needs to keep supporting this sinking ship.
1 · Reply
zigsfrd
zigsfrd Jul. 16 at 2:21 PM
$NSPR The big wait on this is TCAR with recommercialization in between. This thing tests my patience but the idea that the market sees no value in best of class stents is a joke.
1 · Reply
Unleashedz2024
Unleashedz2024 Jul. 15 at 2:47 PM
$NSPR great stent, bad management, need Acquisition
0 · Reply
Latest News on NSPR
InspireMD enrolls first patient in CGUARDIANS III study

2026-06-08T12:07:53.000Z - 7 weeks ago

InspireMD enrolls first patient in CGUARDIANS III study


InspireMD price target lowered to $3 from $4 at Piper Sandler

2026-05-05T11:00:54.000Z - 3 months ago

InspireMD price target lowered to $3 from $4 at Piper Sandler


InspireMD reports Q1 EPS (16c), consensus (18c)

2026-05-04T20:44:33.000Z - 3 months ago

InspireMD reports Q1 EPS (16c), consensus (18c)


InspireMD Earnings Call Transcript: Q1 2026

May 4, 2026, 4:30 PM EDT - 3 months ago

InspireMD Earnings Call Transcript: Q1 2026


InspireMD Earnings release: Q1 2026

May 4, 2026, 4:30 PM EDT - 3 months ago

InspireMD Earnings release: Q1 2026


InspireMD Quarterly report: Q1 2026

May 4, 2026, 4:30 PM EDT - 3 months ago

InspireMD Quarterly report: Q1 2026


InspireMD Reports First Quarter 2026 Financial Results

May 4, 2026, 4:05 PM EDT - 3 months ago

InspireMD Reports First Quarter 2026 Financial Results


InspireMD Slides: Investor presentation

May 4, 2026, 4:00 PM EDT - 3 months ago

InspireMD Slides: Investor presentation


InspireMD price target lowered to $4 from $5 at Lake Street

2026-05-04T13:51:18.000Z - 3 months ago

InspireMD price target lowered to $4 from $5 at Lake Street


InspireMD withdrawing prior FY26 revenue guidance

2026-05-04T13:50:39.000Z - 3 months ago

InspireMD withdrawing prior FY26 revenue guidance


InspireMD to Announce First Quarter 2026 Financial Results

Apr 27, 2026, 4:05 PM EDT - 3 months ago

InspireMD to Announce First Quarter 2026 Financial Results


InspireMD Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 3 months ago

InspireMD Proxy statement: Proxy filing


InspireMD Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 3 months ago

InspireMD Proxy statement: Proxy filing


InspireMD Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 3 months ago

InspireMD Proxy statement: Proxy filing


InspireMD Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 3 months ago

InspireMD Proxy statement: Proxy filing


InspireMD Earnings Call Transcript: Q4 2025

Mar 18, 2026, 8:30 AM EDT - 4 months ago

InspireMD Earnings Call Transcript: Q4 2025


InspireMD Annual report: Q4 2025

Mar 18, 2026, 8:30 AM EDT - 4 months ago

InspireMD Annual report: Q4 2025


InspireMD Earnings release: Q4 2025

Mar 18, 2026, 8:30 AM EDT - 4 months ago

InspireMD Earnings release: Q4 2025


InspireMD reports Q4 EPS (14c), consensus (19c)

2026-03-18T11:11:13.000Z - 4 months ago

InspireMD reports Q4 EPS (14c), consensus (19c)


InspireMD sees FY26 revenue $13M-$15M, consensus $14.55M

2026-03-18T11:10:33.000Z - 4 months ago

InspireMD sees FY26 revenue $13M-$15M, consensus $14.55M


InspireMD participates in a conference call with Lake Street

2026-02-12T15:11:44.000Z - 6 months ago

InspireMD participates in a conference call with Lake Street


InspireMD initiated with a Buy at Maxim

2026-02-02T12:45:07.000Z - 6 months ago

InspireMD initiated with a Buy at Maxim


InspireMD reports inducement grants under Nasdaq listing rule

2026-01-20T14:05:16.000Z - 6 months ago

InspireMD reports inducement grants under Nasdaq listing rule


InspireMD announces publication of C-GUARDIANS trial

2026-01-12T14:20:11.000Z - 7 months ago

InspireMD announces publication of C-GUARDIANS trial


InspireMD announces publication of CREST-2 data in NEJM

2025-11-24T12:45:11.000Z - 8 months ago

InspireMD announces publication of CREST-2 data in NEJM


InspireMD reports inducement grants under Nasdaq listing rule

2025-11-21T14:05:27.000Z - 8 months ago

InspireMD reports inducement grants under Nasdaq listing rule


InspireMD Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

InspireMD Earnings Call Transcript: Q3 2025


InspireMD Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

InspireMD Quarterly report: Q3 2025


InspireMD Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

InspireMD Earnings release: Q3 2025


InspireMD reports Q3 EPS (17c) vs (16c) last year

2025-11-04T12:15:34.000Z - 9 months ago

InspireMD reports Q3 EPS (17c) vs (16c) last year


InspireMD Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 7:00 AM EST - 9 months ago

InspireMD Reports Third Quarter 2025 Financial Results


InspireMD names Peter Soukas as Chief Medical Officer

2025-11-03T12:42:01.000Z - 9 months ago

InspireMD names Peter Soukas as Chief Medical Officer


InspireMD Names Peter A. Soukas, M.D.

Nov 3, 2025, 7:30 AM EST - 9 months ago

InspireMD Names Peter A. Soukas, M.D.


InspireMD to Announce Third Quarter 2025 Financial Results

Oct 21, 2025, 4:05 PM EDT - 10 months ago

InspireMD to Announce Third Quarter 2025 Financial Results


InspireMD Registration statement: Registration Filing

Aug 6, 2025, 8:00 AM EDT - 1 year ago

InspireMD Registration statement: Registration Filing


InspireMD Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 1 year ago

InspireMD Earnings Call Transcript: Q2 2025


InspireMD Earnings release: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 1 year ago

InspireMD Earnings release: Q2 2025


InspireMD Quarterly report: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 1 year ago

InspireMD Quarterly report: Q2 2025


InspireMD Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 8:00 AM EDT - 1 year ago

InspireMD Reports Second Quarter 2025 Financial Results


InspireMD Announces Combined Financings of $58 Million

Jul 31, 2025, 8:30 AM EDT - 1 year ago

InspireMD Announces Combined Financings of $58 Million


InspireMD to Announce Second Quarter 2025 Financial Results

Jul 22, 2025, 7:00 AM EDT - 1 year ago

InspireMD to Announce Second Quarter 2025 Financial Results


InspireMD Earnings Call Transcript: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

InspireMD Earnings Call Transcript: Q1 2025


InspireMD Earnings release: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

InspireMD Earnings release: Q1 2025


InspireMD Quarterly report: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

InspireMD Quarterly report: Q1 2025


InspireMD Reports First Quarter 2025 Financial Results

May 9, 2025, 7:00 AM EDT - 1 year ago

InspireMD Reports First Quarter 2025 Financial Results


InspireMD to Announce First Quarter 2025 Financial Results

Apr 25, 2025, 9:00 AM EDT - 1 year ago

InspireMD to Announce First Quarter 2025 Financial Results


InspireMD Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

InspireMD Proxy statement: Proxy Filing


InspireMD Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

InspireMD Proxy statement: Proxy Filing


InspireMD Registration statement: Registration Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

InspireMD Registration statement: Registration Filing


InspireMD Earnings Call Transcript: Q4 2024

Mar 12, 2025, 8:30 AM EDT - 1 year ago

InspireMD Earnings Call Transcript: Q4 2024


InspireMD Earnings release: Q4 2024

Mar 12, 2025, 8:30 AM EDT - 1 year ago

InspireMD Earnings release: Q4 2024


InspireMD Annual report: Q4 2024

Mar 12, 2025, 8:30 AM EDT - 1 year ago

InspireMD Annual report: Q4 2024


InspireMD Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

InspireMD Earnings Call Transcript: Q3 2024


InspireMD Earnings release: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

InspireMD Earnings release: Q3 2024


InspireMD Quarterly report: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

InspireMD Quarterly report: Q3 2024


InspireMD Earnings Call Transcript: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

InspireMD Earnings Call Transcript: Q2 2024


InspireMD Quarterly report: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

InspireMD Quarterly report: Q2 2024


InspireMD Earnings release: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

InspireMD Earnings release: Q2 2024


InspireMD Earnings Call Transcript: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

InspireMD Earnings Call Transcript: Q1 2024


InspireMD Quarterly report: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

InspireMD Quarterly report: Q1 2024


InspireMD Earnings release: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

InspireMD Earnings release: Q1 2024


InspireMD Proxy statement: Proxy Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

InspireMD Proxy statement: Proxy Filing


InspireMD Proxy statement: Proxy Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

InspireMD Proxy statement: Proxy Filing


InspireMD Earnings Call Transcript: Q4 2023

Mar 6, 2024, 8:30 AM EST - 2 years ago

InspireMD Earnings Call Transcript: Q4 2023


InspireMD Earnings release: Q4 2023

Mar 6, 2024, 8:30 AM EST - 2 years ago

InspireMD Earnings release: Q4 2023


InspireMD Annual report: Q4 2023

Mar 6, 2024, 8:30 AM EST - 2 years ago

InspireMD Annual report: Q4 2023


zigsfrd
zigsfrd Jul. 30 at 2:25 PM
$NSPR With the booming sales we've experienced, don't you wonder what took so long? Gleason was not effective, and no amount of corporate glad handing could cover it.
0 · Reply
GiveHerTheDD
GiveHerTheDD Jul. 30 at 12:13 AM
$NSPR Slimming the board and c-suite for recommercialization seems like a good plan 🙌
1 · Reply
focafoca99
focafoca99 Jul. 29 at 9:10 PM
$NSPR Chief Commercial Officer Shane Gleason will leave after the company eliminated his position, effective July 31. https://www.rapidticker.com/news/nspr-sec-filing-b2261c
0 · Reply
pmitsie
pmitsie Jul. 27 at 4:09 PM
$NSPR Not a pretty chat. I fear the worst.
1 · Reply
Thespectator
Thespectator Jul. 25 at 9:38 PM
$NSPR 1:10 r/s cooking up, any day now 😉
1 · Reply
focafoca99
focafoca99 Jul. 23 at 9:10 PM
$NSPR faced a Nasdaq delisting notice for failing the $1.00 minimum bid price requirement. https://www.rapidticker.com/news/nspr-sec-filing-9d4fa1
0 · Reply
Meterdoc
Meterdoc Jul. 21 at 10:23 PM
$NSPR when is the flush? It’ll be epic!❤️
1 · Reply
GiveHerTheDD
GiveHerTheDD Jul. 19 at 2:26 AM
$NSPR Catherine Jennings, President of Vascular Peripheral at Boston Scientific, just left her position to pursue a new medtech venture. While not really unusual, both Martin and Shane liked her Linkedin post. 👀 Make it happen! That is the reassurance everyone needs to keep supporting this sinking ship.
1 · Reply
zigsfrd
zigsfrd Jul. 16 at 2:21 PM
$NSPR The big wait on this is TCAR with recommercialization in between. This thing tests my patience but the idea that the market sees no value in best of class stents is a joke.
1 · Reply
Unleashedz2024
Unleashedz2024 Jul. 15 at 2:47 PM
$NSPR great stent, bad management, need Acquisition
0 · Reply
BrexitIsStupid
BrexitIsStupid Jul. 15 at 10:07 AM
$NSPR AI doesn't know either. "Cash-rich, but burning: Survives for now, but negative Z-Score and huge losses are red flags. Lottery ticket math: If the turnaround works, the upside is huge; if not, dilution or bankruptcy is a real risk. Not for the faint-hearted: This is a classic “high risk, high reward” microcap—best for traders who thrive on volatility and can stomach deep drawdowns."
1 · Reply
BrexitIsStupid
BrexitIsStupid Jul. 15 at 9:46 AM
$NSPR I hate this company, but I am already a bag holder from the last Reverse Split in April 2021. So I am going to buy more to try and reduce my average from 2.10
3 · Reply
RedDogSailor
RedDogSailor Jul. 13 at 6:48 PM
$NSPR well, it been days since to stopped making new lows. That’s a good sign right?
1 · Reply
GiveHerTheDD
GiveHerTheDD Jul. 13 at 6:40 PM
$NSPR Nasdaq minimum share price deficiency should hit this Friday, which means they will process the letter and PR it next week. It should be priced in at this point, but if not, perhaps the last and best chance to average down before all of the end of the year catalysts, which will with 100% certainty send the stock back above $ 1
1 · Reply
Deng42
Deng42 Jul. 12 at 10:38 PM
0 · Reply
ray1313
ray1313 Jul. 10 at 1:18 AM
$NSPR royal shark is a joke
1 · Reply
JZen_
JZen_ Jul. 9 at 2:39 AM
Secondary Watchlist Thursday 7/9 $RPGL $JLHL $CCHH $LGHL $NSPR - JL
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 8 at 12:11 AM
$NSPR Current Stock Price: $0.71 Contracts to trade: $2.5 NSPR Jul 17 2026 Call Entry: $0.72 Exit: $1.41 ROI: 96% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
GiveHerTheDD
GiveHerTheDD Jul. 7 at 2:57 PM
$NSPR coiling around .70 with what seems to be fully priced negative factors, like the lack of U.S. commercialization, burning cash, and nasdaq min price noncompliance. All 3 of those should be pretty quickly torn down once recommercialization hits. Right now, market cap trading at cash means the market is saying their product has no value, which we know isn't true.
0 · Reply
Jonnie5
Jonnie5 Jul. 6 at 2:36 PM
2 · Reply
ray1313
ray1313 Jul. 4 at 9:29 AM
$NSPR no shark you messed up big here & everywhere else how much you down on this? Yikes!!!!!!!!!!!!!!
0 · Reply
focafoca99
focafoca99 Jul. 2 at 9:38 PM
$NSPR discussed a board resignation as Mr. Raymond W. Cohen steps down, effective July 1. https://www.rapidticker.com/news/nspr-sec-filing-e0fea6
1 · Reply